Diary - News
All news Adocia announces the transformation of its business model
• With its experience on BioChaperone® Lispro, Adocia intends to develop its projects further, at least to Phase 3
• Three new projects targeting major markets are expected to enter clinical trials this year
• Adocia’s portfolio of projects is one of the most differentiated in the industry with a particular focus on improving treatment for people with type 1 diabetes
• Adocia’s innovation strategy based on the reformulation of already approved proteins is reinforced by the current economic environment which imposes constraints on the price of medicine
By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree